Skip to main content
Top
Published in: International Journal of Hematology 4/2019

01-04-2019 | Lymphoma | Original Article

Clinical features at transformation in adult T-cell leukemia–lymphoma with smoldering and chronic types

Authors: Hiroaki Taniguchi, Yoshitaka Imaizumi, Yumi Takasaki, Jun Nakashima, Takeharu Kato, Hidehiro Itonaga, Shinya Sato, Yasushi Sawayama, Koji Ando, Hiroo Hasegawa, Tomoko Hata, Yukiyoshi Moriuchi, Kunihiro Tsukasaki, Yasushi Miyazaki

Published in: International Journal of Hematology | Issue 4/2019

Login to get access

Abstract

Watchful waiting (WW) is among the treatment options indicated for patients with indolent adult T-cell leukemia–lymphoma (ATL). However, we previously showed that the long-term prognosis of patients with smoldering and chronic ATL is often worse than expected, with many undergoing transformation to aggressive ATL. To identify clinical features associated with transformation of smoldering/chronic ATL, we retrospectively analyzed the clinical features of 44 patients (14 smoldering and 30 chronic) who experienced transformation during WW. An elevated lactate dehydrogenase (LDH) value was most often observed (n = 30) at the time of transformation, especially in the chronic type (n = 24). Major organ involvement, lymphadenopathy, and hypercalcemia were shown to be associated with transformation in transformed patients without elevated LDH. The median overall survival time after transformation was only 7.8 months, and the prognosis was poor after transformation in those fulfilling the criteria of acute type, similar to that of de novo aggressive ATL. Laboratory data, such as LDH, and clinical signs including exacerbation of performance status, skin lesions, and lymphadenopathy should all be monitored during WW to ensure appropriate timing of chemotherapy initiation. Identification of optimal predictive markers for transformation and new therapeutic options is warranted to improve outcomes in indolent ATL.
Literature
1.
go back to reference Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217–25.CrossRefPubMed Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217–25.CrossRefPubMed
2.
go back to reference Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.CrossRefPubMed Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.CrossRefPubMed
3.
go back to reference Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7.CrossRefPubMed Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7.CrossRefPubMed
4.
go back to reference Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337–43.CrossRefPubMed Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337–43.CrossRefPubMed
5.
go back to reference Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, reesponse criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–9.CrossRefPubMedPubMedCentral Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, reesponse criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–9.CrossRefPubMedPubMedCentral
6.
go back to reference Yamada Y, Hatta Y, Murata K, et al. Deletion of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778–85.CrossRefPubMed Yamada Y, Hatta Y, Murata K, et al. Deletion of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778–85.CrossRefPubMed
7.
go back to reference Takasaki Y, Yamada Y, Sugahara K, et al. Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation. Br J Haematol. 2003;122:253–9.CrossRefPubMed Takasaki Y, Yamada Y, Sugahara K, et al. Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation. Br J Haematol. 2003;122:253–9.CrossRefPubMed
8.
go back to reference Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood. 2001;97:3875–81.CrossRefPubMed Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood. 2001;97:3875–81.CrossRefPubMed
9.
go back to reference Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39–47.CrossRefPubMed Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39–47.CrossRefPubMed
10.
go back to reference Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131:215–25.CrossRefPubMedPubMedCentral Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131:215–25.CrossRefPubMedPubMedCentral
11.
go back to reference Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534–7.CrossRefPubMed Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534–7.CrossRefPubMed
12.
go back to reference Yamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood. 1983;61:192–9.PubMed Yamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood. 1983;61:192–9.PubMed
13.
go back to reference Tsukasaki K, Ikeda S, Murata K, Maeda T, Atogami S, Sohda H, et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk Res. 1993;17:157–66.CrossRefPubMed Tsukasaki K, Ikeda S, Murata K, Maeda T, Atogami S, Sohda H, et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk Res. 1993;17:157–66.CrossRefPubMed
14.
go back to reference Tsukasaki K, Imaizumi Y, Tokura Y, Ohshima K, Kawai K, Utsunomiya A, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol. 2014;41:26–8.CrossRefPubMed Tsukasaki K, Imaizumi Y, Tokura Y, Ohshima K, Kawai K, Utsunomiya A, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol. 2014;41:26–8.CrossRefPubMed
15.
go back to reference Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, et al. Type of skin eruptionis an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117:3961–7.CrossRefPubMed Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, et al. Type of skin eruptionis an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117:3961–7.CrossRefPubMed
16.
go back to reference Bittencourt AL, da Gracas Vieria M, Brites CR, Farre L, Barbosa HS. Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol. 2007;128:875–82.CrossRefPubMed Bittencourt AL, da Gracas Vieria M, Brites CR, Farre L, Barbosa HS. Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol. 2007;128:875–82.CrossRefPubMed
17.
go back to reference Yoshida N, Karube K, Utsunomiya A, Tsukasaki K, Imaizumi Y, Taira N, et al. Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. Cancer Res. 2014;74:6129–38.CrossRefPubMed Yoshida N, Karube K, Utsunomiya A, Tsukasaki K, Imaizumi Y, Taira N, et al. Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. Cancer Res. 2014;74:6129–38.CrossRefPubMed
18.
go back to reference Bazarbachi A, Plumelle Y, Carlos Ramos J, Torteyoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177–83.CrossRefPubMed Bazarbachi A, Plumelle Y, Carlos Ramos J, Torteyoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177–83.CrossRefPubMed
19.
go back to reference Cook LB, Rowan AG, Demontis MA, Sagawe S, Gillet NA, Melamed A, et al. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma. Int J Hematol. 2018;107:378–82.CrossRefPubMed Cook LB, Rowan AG, Demontis MA, Sagawe S, Gillet NA, Melamed A, et al. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma. Int J Hematol. 2018;107:378–82.CrossRefPubMed
Metadata
Title
Clinical features at transformation in adult T-cell leukemia–lymphoma with smoldering and chronic types
Authors
Hiroaki Taniguchi
Yoshitaka Imaizumi
Yumi Takasaki
Jun Nakashima
Takeharu Kato
Hidehiro Itonaga
Shinya Sato
Yasushi Sawayama
Koji Ando
Hiroo Hasegawa
Tomoko Hata
Yukiyoshi Moriuchi
Kunihiro Tsukasaki
Yasushi Miyazaki
Publication date
01-04-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02602-4

Other articles of this Issue 4/2019

International Journal of Hematology 4/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine